• Avalo Therapeutics Chief Medical Officer Doyle Mittie exercised stock options for 1,000 shares at USD 12.65 on July 27, 2026.
• Mittie sold 1,000 shares at USD 20 the same day.
• Directly held common stock ended at 51,776 shares.
• Directly held stock options ended at 124,750.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001918845-26-000024), on July 29, 2026, and is solely responsible for the information contained therein.